Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Cash from Operations: 2021-2025

Historic Cash from Operations for Biofrontera (BFRI) over the last 5 years, with Sep 2025 value amounting to -$3.8 million.

  • Biofrontera's Cash from Operations fell 202.79% to -$3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.0 million, marking a year-over-year increase of 33.96%. This contributed to the annual value of -$10.3 million for FY2024, which is 58.63% up from last year.
  • As of Q3 2025, Biofrontera's Cash from Operations stood at -$3.8 million, which was down 23.26% from -$3.1 million recorded in Q2 2025.
  • Biofrontera's 5-year Cash from Operations high stood at $112,000 for Q2 2022, and its period low was -$21.0 million during Q4 2021.
  • In the last 3 years, Biofrontera's Cash from Operations had a median value of -$3.7 million in 2023 and averaged -$4.2 million.
  • In the last 5 years, Biofrontera's Cash from Operations spiked by 110.52% in 2022 and then plummeted by 9,318.75% in 2023.
  • Biofrontera's Cash from Operations (Quarterly) stood at -$21.0 million in 2021, then skyrocketed by 60.59% to -$8.3 million in 2022, then declined by 7.24% to -$8.9 million in 2023, then skyrocketed by 88.73% to -$1.0 million in 2024, then plummeted by 202.79% to -$3.8 million in 2025.
  • Its Cash from Operations was -$3.8 million in Q3 2025, compared to -$3.1 million in Q2 2025 and -$4.1 million in Q1 2025.